Daiwa Securities Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-230
| Closed | -$9K | – | 1359 |
|
|
2023
Q2 | $9K | Hold |
230
| – | – | ﹤0.01% | 1146 |
|
|
2023
Q1 | $5K | Hold |
230
| – | – | ﹤0.01% | 1161 |
|
|
2022
Q4 | $6K | Hold |
230
| – | – | ﹤0.01% | 1151 |
|
|
2022
Q3 | $5K | Hold |
230
| – | – | ﹤0.01% | 1167 |
|
|
2022
Q2 | $4K | Buy |
230
+77
| +50% | +$1.21K | ﹤0.01% | 1190 |
|
|
2022
Q1 | $3K | Hold |
153
| – | – | ﹤0.01% | 1234 |
|
|
2021
Q4 | $2K | Hold |
153
| – | – | ﹤0.01% | 1316 |
|
|
2021
Q3 | $2K | Buy |
153
+74
| +94% | +$974 | ﹤0.01% | 1254 |
|
|
2021
Q2 | $1K | Hold |
79
| – | – | ﹤0.01% | 1240 |
|
|
2021
Q1 | $1K | Hold |
79
| – | – | ﹤0.01% | 1251 |
|
|
2020
Q4 | $1K | Buy |
+79
| New | +$1.19K | ﹤0.01% | 1233 |
|
|
2019
Q4 | – | Sell |
-85
| Closed | – | – | 1258 |
|
|
2019
Q3 | $0 | Hold |
85
| – | – | ﹤0.01% | 1209 |
|
|
2019
Q2 | $1K | Hold |
85
| – | – | ﹤0.01% | 1193 |
|
|
2019
Q1 | $2K | Hold |
85
| – | – | ﹤0.01% | 1147 |
|
|
2018
Q4 | $1K | Hold |
85
| – | – | ﹤0.01% | 1136 |
|
|
2018
Q3 | $3K | Hold |
85
| – | – | ﹤0.01% | 1115 |
|
|
2018
Q2 | $3K | Hold |
85
| – | – | ﹤0.01% | 1129 |
|
|
2018
Q1 | $4K | Buy |
+85
| New | +$3.11K | ﹤0.01% | 1094 |
|
Daiwa Securities Group's KDNY Position: Q3 2023 in Review
Daiwa Securities Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 230 shares — an estimated $9K sold.
Daiwa Securities Group first reported a position in KDNY in Q1 2018 and held it in 18 quarters. The position peaked at $9K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Daiwa Securities Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Daiwa Securities Group sold 230 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $9K.
- Daiwa Securities Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2018 and held it in 18 quarters.
- Daiwa Securities Group's Chinook Therapeutics, Inc. Common Stock position peaked at $9K in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Daiwa Securities Group's 13F filing for Q3 2023, filed 1 Nov 2023.